➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Medtronic
Mallinckrodt
Johnson and Johnson
Dow
Moodys

Last Updated: April 11, 2021

DrugPatentWatch Database Preview

Litigation Details for In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES. (D. Kan. 2017)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation COUNSEL: DO NOT ADD PARTIES. (D. Kan. 2017)

Date Filed Document No. Description Snippet Link To Document
2018-01-22 123 Response to Motion subsidiaries, sued Teva for infringing U.S. Patent No. 7,449,012. The claim was amended in November…monopoly resulting from a drug patent; indeed, Defendants have patents only on one of many possible delivery… With their additional patents in place—one of which, U.S. Patent No. 7,794,432, having been sought…stressing that Mylan was adding yet another patent to the already-patented EpiPen device in order to “put in…Intelliject’s e-cue infringed the ‘432 patent, despite that the ‘432 patent was not obtained until September External link to document
2019-06-28 1692 Exhibit 36 6,875.4 5,670.5 6,135.2 6,765.1 …amp; Hnath, G. M., “Patent Valuation Analysis—Patent Forward Citations and Patent Quality,” retrieved …. Economics expert in patent suit (declaratory judgment and counterclaim patent infringement suit) involving…buyers in California. 2009: In re Patent of Hee Young Yun, et al., U.S. Patent and Trademark Office, 90/008…commercial success of patents for liquid crystal display (LCD) modules as part of patent reexamination process External link to document
2019-08-22 1848 Memorandum in Support of Motion EpiPen patents, U.S. Patent Nos. 7,449,012 (the “’012 Patent”) and 7,794,432 (the “’432 Patent”).2 Prior…opines on the validity of the ’432 patent, but fails to apply accepted patent validity legal principles. Indeed… history to conclude that “the patent claims of the ’432 patent [were] quite weak, … the ’432 patent after the KSR decision. Thus, the PTO agreed the invention was patentable even under… Analyzing Patent Validity Professor Torrance posits that the ’432 patent is “quite weak External link to document
2020-02-26 2018 Memorandum & Order - Unsealed Copy sued Teva for infringing U.S. Patent No. 7,449,012 (“the Teva patent litigation”). In November 2010,… Patent Infringement Lawsuits The Pfizer defendants own the patents protecting the…that end, defendants allegedly added patents to the already-patented EpiPen to stop generic competitors.…secured ’432 patent. Later, King and Meridian dropped their claims based on the ’012 patent, leaving only…claims for the ’432 patent. On April 27, 2012, the parties settled the Teva patent litigation. According External link to document
2021-01-15 2298 Exhibit C 6,875.4 5,670.5 6,135.2 6,765.1 Income Tax Expense 1,460.9…amp; Hnath, G. M., “Patent Valuation Analysis—Patent Forward Citations and Patent Quality,” retrieved …. Economics expert in patent suit (declaratory judgment and counterclaim patent infringement suit) involving…buyers in California. 2009: In re Patent of Hee Young Yun, et al., U.S. Patent and Trademark Office, 90/008…commercial success of patents for liquid crystal display (LCD) modules as part of patent reexamination process External link to document
2017-10-17 60 Amended Complaint 8, 2009) alleging infringement of U.S. Patent No. 7,449,012. King filed a First Amended Complaint on…equivalents, and any patents that purportedly protect each drug. 113. Drug patents typically last…ordinary patent term of twenty years, often compensate for unfairness in the ordinary patent process …not infringe any patents claiming to cover the reference product because: (1) no patents are listed in …drug until all applicable patents have expired; or (4) all applicable patents are invalid or will not External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Dow
Mallinckrodt
McKinsey
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.